SS-31
Cardiolipin Stabilization & Mitochondrial Membrane Protection
What is SS-31?
SS-31, also known as elamipretide (and by the research designation MTP-131), is a synthetic mitochondria-targeting tetrapeptide. Its defining feature is a specific affinity for cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential to the structural organization of the cristae — the folded membranes where the electron transport chain and ATP synthesis are housed. By binding cardiolipin, SS-31 is proposed to help stabilize inner-membrane architecture and support the efficiency of the respiratory machinery, particularly in mitochondria that are aged, stressed, or dysfunctional.
Research on SS-31 spans a wide range of preclinical models covering cardiac, renal, muscular, and neurological tissue. A recurring theme in this literature is the reduction of mitochondrial reactive oxygen species (ROS) and oxidative stress, alongside reports of improved ATP production efficiency and preserved membrane potential in damaged or aged mitochondria. Because mitochondrial dysfunction is implicated in ischemia-reperfusion injury, heart failure, and various age-related conditions, SS-31 has been examined as a research tool for probing these pathways. Notably, unlike most compounds in this category, elamipretide has advanced into human clinical trials — including studies in primary mitochondrial disease (such as primary mitochondrial myopathy) and certain cardiac and ophthalmic conditions. Results across these trials have been mixed, with some endpoints not reaching statistical significance, which underscores that its clinical value remains under active investigation and unproven.
The distinction between mechanism and outcome matters here. The cardiolipin-binding mechanism is relatively well characterized in biochemical terms, but demonstrating consistent, meaningful benefit in humans is a separate and still-open question. Elamipretide is an investigational agent that has not received general regulatory approval as a therapy. SS-31 is offered strictly for laboratory research and educational purposes only; nothing here constitutes medical advice or an endorsement of human use.
Molecular data
Mechanism of action
In preclinical research, SS-31 is associated with the following pathways and targets:
Research highlights
- Binds cardiolipin to stabilize inner mitochondrial membrane
- Reduces mitochondrial ROS production and oxidative stress
- Improves ATP synthesis efficiency in aged mitochondria
- Cardioprotective effects in ischemia-reperfusion models
Frequently asked questions
How does SS-31 protect mitochondria?
SS-31 selectively binds cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane that helps organize the cristae and the electron transport chain. By associating with cardiolipin, it is proposed to stabilize inner-membrane structure, support electron transport efficiency, and reduce the leakage of reactive oxygen species. These mechanisms are drawn primarily from biochemical and preclinical studies.
What is the difference between SS-31 and elamipretide?
They are the same molecule. SS-31 is the research designation (part of the Szeto-Schiller peptide series), while elamipretide is the drug-development name; MTP-131 is another identifier used in trials. The naming simply reflects the compound moving from basic research into clinical investigation.
Has SS-31 been tested in humans?
Yes. Unlike many peptides in this category, elamipretide has been studied in human clinical trials, including in primary mitochondrial disease and certain cardiac and eye conditions. Trial outcomes have been mixed, with some studies not meeting their primary endpoints, so its clinical usefulness is still considered unproven and under investigation.
Why is cardiolipin important to how SS-31 works?
Cardiolipin is a signature lipid of the inner mitochondrial membrane and is critical for maintaining cristae shape and the function of the respiratory complexes embedded there. In aged or damaged mitochondria, cardiolipin can be disrupted. SS-31's affinity for cardiolipin is the basis for the hypothesis that it helps preserve mitochondrial structure and energy output.
Is SS-31 approved for medical use?
No. Elamipretide/SS-31 remains an investigational compound and has not received general regulatory approval as a therapy. It is supplied for laboratory research and educational purposes only, and none of this information should be taken as medical advice or guidance for human use.
Source SS-31 at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop SS-31 at Purgo Labs ↗Related compounds
For research and educational purposes only. SS-31 is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.